Sitagliptin / Metformin hydrochloride Accord

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Shusha Taarifa za kipeperushi (PIL)
01-09-2022
Shusha Tabia za bidhaa (SPC)
01-09-2022
Shusha Ripoti ya Tathmini ya umma (PAR)
03-08-2022

Viambatanisho vya kazi:

metformin hydrochloride, sitagliptin hydrochloride monohydrate

Inapatikana kutoka:

Accord Healthcare S.L.U.

ATC kanuni:

A10BD07

INN (Jina la Kimataifa):

sitagliptin, metformin hydrochloride

Kundi la matibabu:

Drugs used in diabetes

Eneo la matibabu:

Diabetes Mellitus, Type 2

Matibabu dalili:

For adult patients with type 2 diabetes mellitus:It is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.It is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.It is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.It is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Bidhaa muhtasari:

Revision: 1

Idhini hali ya:

Authorised

Idhini ya tarehe:

2022-07-22

Taarifa za kipeperushi

                                35
B. PACKAGE LEAFLET
36
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SITAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD 50 MG/850 MG
FILM-COATED TABLETS
SITAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD 50 MG/1,000 MG
FILM-COATED TABLETS
sitagliptin/metformin hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist, or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Sitagliptin/Metformin hydrochloride Accord is and what it is used
for
2.
What you need to know before you take Sitagliptin/Metformin
hydrochloride Accord
3.
How to take Sitagliptin/Metformin hydrochloride Accord
4.
Possible side effects
5.
How to store Sitagliptin/Metformin hydrochloride Accord
6.
Contents of the pack and other information
1.
WHAT SITAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD IS AND WHAT IT IS USED
FOR
This medicine contains two different medicines called sitagliptin and
metformin.
•
sitagliptin belongs to a class of medicines called DPP-4 inhibitors
(dipeptidyl peptidase-4
inhibitors)
•
metformin belongs to a class of medicines called biguanides.
They work together to control blood sugar levels in adult patients
with a form of diabetes called
‘type 2 diabetes mellitus’. This medicine helps to increase the
levels of insulin produced after a meal
and lowers the amount of sugar made by your body.
Along with diet and exercise, this medicine helps lower your blood
sugar. This medicine can be used
alone or with certain other medicines for diabetes (insulin,
sulphonylureas, or glitazones).
What is type 2 diabetes?
Type 2 diabetes is a condition in which your body
                                
                                Soma hati kamili

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Sitagliptin/Metformin hydrochloride Accord 50 mg/850 mg film-coated
tablets
Sitagliptin/Metformin hydrochloride Accord 50 mg/1,000 mg film-coated
tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Sitagliptin/Metformin hydrochloride Accord 50 mg/850 mg film-coated
tablets
Each tablet contains sitagliptin hydrochloride monohydrate equivalent
to 50 mg of sitagliptin and
850 mg of metformin hydrochloride.
Sitagliptin/Metformin hydrochloride Accord 50 mg/1,000 mg film-coated
tablets
Each tablet contains sitagliptin hydrochloride monohydrate equivalent
to 50 mg of sitagliptin and
1,000 mg of metformin hydrochloride.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Sitagliptin/Metformin hydrochloride Accord 50 mg/850 mg film-coated
tablets
Pink colored, capsule shaped, film coated tablet debossed with 'SM2'
on one side and plain on other
side. Dimension: 20x10 mm.
Sitagliptin/Metformin hydrochloride Accord 50 mg/1,000 mg film-coated
tablets
Red colored, capsule shaped, film coated tablet debossed with 'SM3' on
one side and plain on other
side. Dimension: Length: 21x10 mm
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For adult patients with type 2 diabetes mellitus:
It is indicated as an adjunct to diet and exercise to improve
glycaemic control in patients inadequately
controlled on their maximal tolerated dose of metformin alone or those
already being treated with the
combination of sitagliptin and metformin.
It is indicated in combination with a sulphonylurea (i.e., triple
combination therapy) as an adjunct to
diet and exercise in patients inadequately controlled on their maximal
tolerated dose of metformin and
a sulphonylurea.
It is indicated as triple combination therapy with a peroxisome
proliferator-activated receptor gamma
(PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and
exercise in patients inadequately
controlled on their maximal tolerated dose of metf
                                
                                Soma hati kamili

Bidhaa zinazofanana

Viambatanisho vya kazi metformin hydrochloride, sitagliptin hydrochloride monohydrate

metformin hydrochloride, sitagliptin hydrochloride monohydrate

ATC kanuni A10BD07

A10BD07

Mzalishaji au wazalishaji wadogowadogo Accord Healthcare S.L.U.

Accord Healthcare S.L.U.

INN (Jina la Kimataifa) sitagliptin, metformin hydrochloride

sitagliptin, metformin hydrochloride

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kibulgaria 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kihispania 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kicheki 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kidenmaki 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kijerumani 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kiestonia 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kigiriki 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kifaransa 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kiitaliano 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kilatvia 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kilithuania 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kihungari 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kimalta 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kiholanzi 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kipolandi 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kireno 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kiromania 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kislovakia 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kislovenia 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kifinlandi 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kiswidi 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 03-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kinorwe 01-09-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 01-09-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 01-09-2022
Tabia za bidhaa Tabia za bidhaa Kroeshia 01-09-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 03-08-2022

Tafuta arifu zinazohusiana na bidhaa hii

Taadhari Sitagliptin Metformin hydrochloride Accord hydrochloride, monohydrate sitagliptin,

Sitagliptin Metformin hydrochloride Accord hydrochloride, monohydrate sitagliptin,

Tazama historia ya hati

Historia ya nyaraka Historia ya nyaraka

Sitagliptin / Metformin hydrochloride Accord